Elisabeth J Ruijgrok

Summary

Country: The Netherlands

Publications

  1. ncbi Nebulized amphotericin B combined with intravenous amphotericin B in rats with severe invasive pulmonary aspergillosis
    Elisabeth J Ruijgrok
    Department of Clinical Pharmacy, Medical Center Rijnmond Zuid, Olympiaweg 350, 3078 HT Rotterdam, The Netherlands
    Antimicrob Agents Chemother 50:1852-4. 2006
  2. ncbi Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial
    Bart J Rijnders
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Clin Infect Dis 46:1401-8. 2008
  3. ncbi Nebulization of four commercially available amphotericin B formulations in persistently granulocytopenic rats with invasive pulmonary aspergillosis: evidence for long-term biological activity
    Elisabeth J Ruijgrok
    Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center Rotterdam, Dr Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands
    J Pharm Pharmacol 57:1289-95. 2005

Detail Information

Publications3

  1. ncbi Nebulized amphotericin B combined with intravenous amphotericin B in rats with severe invasive pulmonary aspergillosis
    Elisabeth J Ruijgrok
    Department of Clinical Pharmacy, Medical Center Rijnmond Zuid, Olympiaweg 350, 3078 HT Rotterdam, The Netherlands
    Antimicrob Agents Chemother 50:1852-4. 2006
    ..Nebulized liposomal AMB in addition to intravenous AMB resulted in significantly prolonged survival compared to controls...
  2. ncbi Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial
    Bart J Rijnders
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Clin Infect Dis 46:1401-8. 2008
    ..Because pulmonary deposition of conidia is the first step in developing IPA, we hypothesized that inhalation of liposomal amphotericin B would prevent IPA...
  3. ncbi Nebulization of four commercially available amphotericin B formulations in persistently granulocytopenic rats with invasive pulmonary aspergillosis: evidence for long-term biological activity
    Elisabeth J Ruijgrok
    Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center Rotterdam, Dr Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands
    J Pharm Pharmacol 57:1289-95. 2005
    ..All commercially available amphotericin B preparations could be nebulized efficiently and may be of value in the prophylactic treatment of invasive pulmonary aspergillosis...